TY - JOUR
T1 - Deleted in liver cancer-1 (DLC1)
T2 - An emerging metastasis suppressor gene
AU - Popescu, Nicholas C.
AU - Goodison, Steve
N1 - Funding Information:
Acknowledgments Supported in part by National Cancer Institute Grants RO1 CA116161 (SG) and R44 CA173921 (SG). Dr. Popescu is a co-inventor on a patent for the potential use of DLC1 in oncology. Dr. Goodison has no conflicts to disclose.
PY - 2014/6
Y1 - 2014/6
N2 - While significant progress continues to be made in the early detection and therapeutic management of primary tumors, the incidence of metastatic disease remains the major cause of mortality. Accordingly, the development of novel effective therapies that can ameliorate dissemination and secondary tumor growth are a clinical priority. The identification of genetic and functional alterations in cancer cells that affect factors implicated in the metastatic process is critical for designing preventive and therapeutic strategies. Evidence implicating the protein deleted in liver cancer-1 (DLC1), a Rho GTPase activator, in metastasis has accumulated to a point where DLC1 may be considered as a metastasis suppressor gene. This review presents evidence supporting an anti-metastatic role for DLC1 in several human cancers and discusses the mechanisms contributing to its inhibitory effects. In addition, promising opportunities for therapeutic interventions based on DLC1 function and downstream pathways involved in the metastatic process are considered.
AB - While significant progress continues to be made in the early detection and therapeutic management of primary tumors, the incidence of metastatic disease remains the major cause of mortality. Accordingly, the development of novel effective therapies that can ameliorate dissemination and secondary tumor growth are a clinical priority. The identification of genetic and functional alterations in cancer cells that affect factors implicated in the metastatic process is critical for designing preventive and therapeutic strategies. Evidence implicating the protein deleted in liver cancer-1 (DLC1), a Rho GTPase activator, in metastasis has accumulated to a point where DLC1 may be considered as a metastasis suppressor gene. This review presents evidence supporting an anti-metastatic role for DLC1 in several human cancers and discusses the mechanisms contributing to its inhibitory effects. In addition, promising opportunities for therapeutic interventions based on DLC1 function and downstream pathways involved in the metastatic process are considered.
UR - http://www.scopus.com/inward/record.url?scp=84902362250&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902362250&partnerID=8YFLogxK
U2 - 10.1007/s40291-014-0086-3
DO - 10.1007/s40291-014-0086-3
M3 - Review article
C2 - 24519699
AN - SCOPUS:84902362250
SN - 1177-1062
VL - 18
SP - 293
EP - 302
JO - Molecular Diagnosis and Therapy
JF - Molecular Diagnosis and Therapy
IS - 3
ER -